Compositions and methods for TCR reprogramming using fusion proteins

Abstract

Provided herein are recombinant nucleic acids encoding a T cell receptor (TCR) fusion protein (TFP), modified human immune cells expressing the encoded molecules, and methods of their use in the treatment of diseases, including cancer.

Description

[0001] cross reference [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 836,977, filed April 22, 2019, and U.S. Provisional Application No. 62 / 943,679, filed December 4, 2019, each of which is incorporated herein by reference in its entirety. Background technique [0003] Cancer is the leading cause of death in the United States and elsewhere. Depending on the type of cancer, treatment is usually done with surgery, chemotherapy, and / or radiation. These treatments often fail, and new treatments are clearly needed, either alone or in combination with the current standard of care. [0004] Most patients with hematologic malignancies or advanced solid tumors are not cured with standard therapies. Furthermore, traditional treatment options often have severe side effects. Many attempts have been made to make a patient's immune system reject cancer cells, an approach collectively known as cancer immunotherapy. [0005] The success of engineered ...

AI Technical Summary

Problems solved by technology

[0011] Recognized herein is the need for delivery of biological forms to address deficiencies surrounding the regulation of intracellular translation and processing of nucleic acids encoding polypeptides, and thus optimize protein expression from the delivery form

Images